TY - JOUR
T1 - Japanese clinical practice guidelines for congenital biliary dilatation
AU - the Japanese Study Group on Congenital Biliary Dilatation (JSCBD)
AU - Ishibashi, Hiroki
AU - Shimada, Mitsuo
AU - Kamisawa, Terumi
AU - Fujii, Hideki
AU - Hamada, Yoshinori
AU - Kubota, Masayuki
AU - Urushihara, Naoto
AU - Endo, Itaru
AU - Nio, Masaki
AU - Taguchi, Tomoaki
AU - Ando, Hisami
N1 - Publisher Copyright:
© 2017 Japanese Society of Hepato-Biliary-Pancreatic Surgery
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Until now, there have been no practical clinical guidelines for congenital biliary dilatation (CBD). In this review article, the Japanese Study Group on Congenital Biliary Dilatation (JSCBD) propose to establish clinical practice guidelines for CBD. Because the evidence-based literature is relatively small, we decided to create guidelines based on the consensus of experts, using the medical literature for reference. A total of 20 clinical questions (CQs) were considered by the members of the editorial committee responsible for the guidelines. The CQs included the distinct aspects of CBD: (1) Concepts and Pathology (three CQs); (2) Diagnosis (six CQs); (3) Pancreaticobiliary Complications (three CQs); Treatments and Prognosis (eight CQs). Each statements and comments for CQs were made by the guidelines committee members. CQs were finally approved after review by members of the editorial committee and the guidelines evaluation board of CBD. These guidelines were created to provide assistance in the clinical practice of CBD management; their contents focus on clinical utility, and they include general information on CBD to make this disease more widely recognized.
AB - Until now, there have been no practical clinical guidelines for congenital biliary dilatation (CBD). In this review article, the Japanese Study Group on Congenital Biliary Dilatation (JSCBD) propose to establish clinical practice guidelines for CBD. Because the evidence-based literature is relatively small, we decided to create guidelines based on the consensus of experts, using the medical literature for reference. A total of 20 clinical questions (CQs) were considered by the members of the editorial committee responsible for the guidelines. The CQs included the distinct aspects of CBD: (1) Concepts and Pathology (three CQs); (2) Diagnosis (six CQs); (3) Pancreaticobiliary Complications (three CQs); Treatments and Prognosis (eight CQs). Each statements and comments for CQs were made by the guidelines committee members. CQs were finally approved after review by members of the editorial committee and the guidelines evaluation board of CBD. These guidelines were created to provide assistance in the clinical practice of CBD management; their contents focus on clinical utility, and they include general information on CBD to make this disease more widely recognized.
UR - http://www.scopus.com/inward/record.url?scp=85011601826&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85011601826&partnerID=8YFLogxK
U2 - 10.1002/jhbp.415
DO - 10.1002/jhbp.415
M3 - Article
C2 - 28111910
AN - SCOPUS:85011601826
SN - 1868-6974
VL - 24
SP - 1
EP - 16
JO - Journal of Hepato-Biliary-Pancreatic Sciences
JF - Journal of Hepato-Biliary-Pancreatic Sciences
IS - 1
ER -